vs
美国运通（AXP）与礼来（LLY）财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是美国运通的1020.4倍（$19.3B vs $18.9M），礼来净利率更高（34.4% vs 15.7%，领先18.7%），礼来同比增速更快（42.6% vs 11.4%），过去两年礼来的营收复合增速更高（48.3% vs -95.6%）
美国运通是全球知名的支付服务提供商，主营签账卡、信用卡产品及旅行相关服务，下设全球消费者服务、全球商业服务、全球商户与网络服务三大业务板块，还提供支付融资、网络服务、应付账款费用管理、旅行生活服务等多元解决方案。
礼来（Eli Lilly and Company）是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，1876年由美国内战时期联邦军退伍药剂师伊莱·礼来创立，目前在18个国家设有办事处，产品销往全球约125个国家，是全球知名的制药厂商。
AXP vs LLY — 直观对比
营收规模更大
LLY
是对方的1020.4倍
$18.9M
营收增速更快
LLY
高出31.1%
11.4%
净利率更高
LLY
高出18.7%
15.7%
两年增速更快
LLY
近两年复合增速
-95.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.9M | $19.3B |
| 净利润 | $3.0M | $6.6B |
| 毛利率 | — | 82.5% |
| 营业利润率 | — | 42.8% |
| 净利率 | 15.7% | 34.4% |
| 营收同比 | 11.4% | 42.6% |
| 净利润同比 | 15.0% | 50.5% |
| 每股收益（稀释后） | — | $7.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXPLLY
| Q1 26 | $18.9M | — | ||
| Q4 25 | $10.9B | $19.3B | ||
| Q3 25 | $10.4B | $17.6B | ||
| Q2 25 | $10.3B | $15.6B | ||
| Q1 25 | $9.6B | $12.7B | ||
| Q4 24 | $10.0B | $13.5B | ||
| Q3 24 | $9.7B | $11.4B | ||
| Q2 24 | $9.8B | $11.3B |
净利润AXPLLY
| Q1 26 | $3.0M | — | ||
| Q4 25 | $2.5B | $6.6B | ||
| Q3 25 | $2.9B | $5.6B | ||
| Q2 25 | $2.9B | $5.7B | ||
| Q1 25 | $2.6B | $2.8B | ||
| Q4 24 | $2.2B | $4.4B | ||
| Q3 24 | $2.5B | $970.3M | ||
| Q2 24 | $3.0B | $3.0B |
毛利率AXPLLY
| Q1 26 | — | — | ||
| Q4 25 | — | 82.5% | ||
| Q3 25 | — | 82.9% | ||
| Q2 25 | — | 84.3% | ||
| Q1 25 | — | 82.5% | ||
| Q4 24 | — | 82.2% | ||
| Q3 24 | — | 81.0% | ||
| Q2 24 | — | 80.8% |
营业利润率AXPLLY
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | 42.8% | ||
| Q3 25 | 36.7% | 41.1% | ||
| Q2 25 | 34.4% | 43.6% | ||
| Q1 25 | 34.6% | 27.2% | ||
| Q4 24 | 27.7% | 37.2% | ||
| Q3 24 | 33.0% | 13.9% | ||
| Q2 24 | 38.6% | 31.1% |
净利率AXPLLY
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | 34.4% | ||
| Q3 25 | 27.9% | 31.7% | ||
| Q2 25 | 28.0% | 36.4% | ||
| Q1 25 | 26.8% | 21.7% | ||
| Q4 24 | 21.8% | 32.6% | ||
| Q3 24 | 25.8% | 8.5% | ||
| Q2 24 | 30.7% | 26.3% |
每股收益（稀释后）AXPLLY
| Q1 26 | — | — | ||
| Q4 25 | $3.52 | $7.39 | ||
| Q3 25 | $4.14 | $6.21 | ||
| Q2 25 | $4.08 | $6.29 | ||
| Q1 25 | $3.64 | $3.06 | ||
| Q4 24 | $3.04 | $4.88 | ||
| Q3 24 | $3.49 | $1.07 | ||
| Q2 24 | $4.15 | $3.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $7.3B |
| 总债务越低越好 | $60.4M | — |
| 股东权益账面价值 | $34.0M | $26.5B |
| 总资产 | $308.9M | $112.5B |
| 负债/权益比越低杠杆越低 | 1.78× | — |
8季度趋势，按日历期对齐
现金及短期投资AXPLLY
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | $7.3B | ||
| Q3 25 | $1.3B | $9.9B | ||
| Q2 25 | $197.0M | $3.5B | ||
| Q1 25 | $261.0M | $3.2B | ||
| Q4 24 | $221.0M | $3.4B | ||
| Q3 24 | $120.0M | $3.5B | ||
| Q2 24 | $188.0M | $3.4B |
总债务AXPLLY
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | — | ||
| Q3 25 | $57.8B | — | ||
| Q2 25 | $58.2B | — | ||
| Q1 25 | $51.2B | — | ||
| Q4 24 | $49.7B | $29.5B | ||
| Q3 24 | $53.5B | — | ||
| Q2 24 | $51.5B | — |
股东权益AXPLLY
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | $26.5B | ||
| Q3 25 | $32.4B | $23.8B | ||
| Q2 25 | $32.3B | $18.3B | ||
| Q1 25 | $31.2B | $15.8B | ||
| Q4 24 | $30.3B | $14.2B | ||
| Q3 24 | $29.7B | $14.2B | ||
| Q2 24 | $29.5B | $13.6B |
总资产AXPLLY
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | $112.5B | ||
| Q3 25 | $297.6B | $114.9B | ||
| Q2 25 | $295.6B | $100.9B | ||
| Q1 25 | $282.2B | $89.4B | ||
| Q4 24 | $271.5B | $78.7B | ||
| Q3 24 | $271.0B | $75.6B | ||
| Q2 24 | $272.2B | $71.9B |
负债/权益比AXPLLY
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.80× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | 1.64× | 2.08× | ||
| Q3 24 | 1.80× | — | ||
| Q2 24 | 1.74× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $3.2B |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.49× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AXPLLY
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $3.2B | ||
| Q3 25 | $6.2B | $8.8B | ||
| Q2 25 | $4.4B | $3.1B | ||
| Q1 25 | $4.8B | $1.7B | ||
| Q4 24 | $5.8B | $2.5B | ||
| Q3 24 | $-1.8B | $3.7B | ||
| Q2 24 | $4.5B | $1.5B |
自由现金流AXPLLY
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $5.6B | — | ||
| Q2 25 | $3.7B | — | ||
| Q1 25 | $4.3B | — | ||
| Q4 24 | $5.3B | — | ||
| Q3 24 | $-2.3B | — | ||
| Q2 24 | $4.0B | — |
自由现金流率AXPLLY
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | — | ||
| Q3 25 | 53.6% | — | ||
| Q2 25 | 36.3% | — | ||
| Q1 25 | 45.0% | — | ||
| Q4 24 | 53.1% | — | ||
| Q3 24 | -23.3% | — | ||
| Q2 24 | 40.4% | — |
资本支出强度AXPLLY
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 6.3% | — | ||
| Q2 25 | 6.0% | — | ||
| Q1 25 | 4.5% | — | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 4.7% | — | ||
| Q2 24 | 5.8% | — |
现金转化率AXPLLY
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | 0.49× | ||
| Q3 25 | 2.15× | 1.58× | ||
| Q2 25 | 1.51× | 0.55× | ||
| Q1 25 | 1.84× | 0.60× | ||
| Q4 24 | 2.66× | 0.56× | ||
| Q3 24 | -0.72× | 3.83× | ||
| Q2 24 | 1.50× | 0.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
LLY
| Other | $5.4B | 28% |
| Zepbound | $4.2B | 22% |
| Mounjaro | $4.1B | 21% |
| Verzenio | $997.1M | 5% |
| Collaborationand Other Revenue | $991.7M | 5% |
| Taltz | $724.3M | 4% |
| Trulicity | $692.8M | 4% |
| Other Cardiometabolic Health | $524.5M | 3% |
| Other Oncology | $514.8M | 3% |
| Jardiance | $465.8M | 2% |
| Neuroscience | $320.2M | 2% |
| Other Immunology | $187.3M | 1% |
| Other Product Total | $77.0M | 0% |
